Surgical Treatment for Encapsulating Peritoneal Sclerosis: 24 Years' Experience.


Journal

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis
ISSN: 1718-4304
Titre abrégé: Perit Dial Int
Pays: United States
ID NLM: 8904033

Informations de publication

Date de publication:
Historique:
received: 27 02 2018
accepted: 17 04 2018
pubmed: 12 7 2018
medline: 3 1 2020
entrez: 12 7 2018
Statut: ppublish

Résumé

Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis. The mortality rate for EPS is high, primarily due to complications related to bowel obstruction. Surgery was previously contraindicated; however, surgical enterolysis is performed for patients in whom bowel obstruction fails to improve. This was a retrospective observational study of patients with EPS who received surgical intervention at a single center between November 1993 and October 2017. The severity of intestine damage was characterized by grade-3 peritoneal calcification on abdominal computed tomography (CT) scan and degeneration of the small intestinal wall in surgery. Two-hundred and forty-three patients with EPS opted for surgery. Among them, 58 had recurrence and required re-surgery; a total of 318 EPS surgeries were performed. Death was related to EPS in 61 patients (25.1%), of whom 15 died postoperatively. Sixty-seven patients (27.6%) died from other causes. The actuarial survival rates at 1, 2, 3, 5, and 8 years after EPS diagnosis were 91%, 83%, 77%, 66%, and 53% respectively. The 50% actuarial survival points after EPS diagnosis and surgery were 104 months and 85 months, respectively. Peritoneal calcification and small intestinal wall degeneration grading showed significant association with the mortality curve for EPS-related death. Excellent outcomes for EPS are achieved with surgery. The degree of peritoneal deterioration affected the clinical outcomes. Currently, EPS is no longer recognized as a fatal complication.

Sections du résumé

BACKGROUND
Encapsulating peritoneal sclerosis (EPS) is a serious complication of long-term peritoneal dialysis. The mortality rate for EPS is high, primarily due to complications related to bowel obstruction. Surgery was previously contraindicated; however, surgical enterolysis is performed for patients in whom bowel obstruction fails to improve.
METHODS
This was a retrospective observational study of patients with EPS who received surgical intervention at a single center between November 1993 and October 2017. The severity of intestine damage was characterized by grade-3 peritoneal calcification on abdominal computed tomography (CT) scan and degeneration of the small intestinal wall in surgery.
RESULTS
Two-hundred and forty-three patients with EPS opted for surgery. Among them, 58 had recurrence and required re-surgery; a total of 318 EPS surgeries were performed. Death was related to EPS in 61 patients (25.1%), of whom 15 died postoperatively. Sixty-seven patients (27.6%) died from other causes. The actuarial survival rates at 1, 2, 3, 5, and 8 years after EPS diagnosis were 91%, 83%, 77%, 66%, and 53% respectively. The 50% actuarial survival points after EPS diagnosis and surgery were 104 months and 85 months, respectively. Peritoneal calcification and small intestinal wall degeneration grading showed significant association with the mortality curve for EPS-related death.
CONCLUSION
Excellent outcomes for EPS are achieved with surgery. The degree of peritoneal deterioration affected the clinical outcomes. Currently, EPS is no longer recognized as a fatal complication.

Identifiants

pubmed: 29991561
pii: pdi.2018.00042
doi: 10.3747/pdi.2018.00042
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-174

Informations de copyright

Copyright © 2019 International Society for Peritoneal Dialysis.

Auteurs

Hideki Kawanishi (H)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Naka-ku, Hiroshima, Japan h-kawanishi@tuschiya-hp.jp.
Faculty of Medicine, Hiroshima University, Minami-ku, Hiroshima, Japan.

Masataka Banshodani (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Naka-ku, Hiroshima, Japan.

Masahiro Yamashita (M)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Naka-ku, Hiroshima, Japan.

Sadanori Shintaku (S)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Naka-ku, Hiroshima, Japan.

Kiyohiko Dohi (K)

Department of Artificial Organs, Akane-Foundation, Tsuchiya General Hospital, Naka-ku, Hiroshima, Japan.
Faculty of Medicine, Hiroshima University, Minami-ku, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH